A Phase 4 interventional study of Norfloxacin 400 MG and Nitazoxanide 500 MG in Spontaneous Bacterial Peritonitis, Cirrhoses, Liver and Ascites, sponsored by Tanta University. Completed at 1 site in Egypt. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-02-14.
Sponsored by Tanta University · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Ascites with a site in Egypt — 2 open to participants now, 2 under way, 1 of them phase 3. Ascites · Egypt.
Among the 13 studies in Ascites with a site in Egypt, this one is one of 2 that started in 2021, is the only one in phase 4, and was the 11th registered.
248 studies on the registry are indexed under Ascites; 57 are open to participants now.
Browse Ascites studies →2 of the 13 studies in Ascites with a site in Egypt are open now. Recruiting first, the newest first:
Beni-Suef University · Sites in Egypt
Ages 18+
Sohag University · Sites in Egypt
Ages 18+
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 40 Ascites studies recruiting now, 21 (53%) set no upper age limit and 12 (30%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 50 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 4 · Phase 4 1
First in 2013; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 90 is above the median of 54 across 180 interventional studies indexed under Ascites.
Median enrollment 90 across the 9 interventional studies, 100 across the 4 observational. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 13 has an industry lead sponsor. The 10 most frequent:
Tanta University is the lead sponsor of 1,014 studies on the registry; 320 are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Tanta University has 2 studies filed under Ascites — fewer than ten, so there is no comparison to draw.
1 of the studies in Ascites with a site in Egypt that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07684326Phase 3Beni-Suef University"Exploring the Potential Benefits of Using Dapagliflozin in Cirrhotic Chronic Liver Disease Patients- A Randomized Controlled Trial" | 2027-07 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies in Ascites with a site in Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if norfloxacin, nitazoxanide, and colistin work as secondary prophylactic agents for spontaneous bacterial peritonitis (SBP) in cirrhotic patients with ascites. It also aims to evaluate the safety and effectiveness of these treatments. The main questions it aims to answer are:
Are nitazoxanide and colistin as effective as norfloxacin in preventing recurrent SBP?
What medical outcomes do participants experience when taking norfloxacin, nitazoxanide, or colistin?
Researchers will compare norfloxacin, nitazoxanide, and colistin to determine their effectiveness in preventing SBP recurrence in cirrhotic patients.
Participants will:
Be randomly assigned to receive either 400 mg norfloxacin daily, 500 mg nitazoxanide twice daily, or 15 ml colistin syrup three times daily (2.25 MIU total per day).
Undergo regular blood tests and ascitic fluid analysis at discharge, 2 months, and 6 months post-treatment.
Be monitored for any side effects and recurrence of SBP.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Success Criteria: A ≥50% reduction in CRP within 3 months is considered a positive response.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
patients to receive norflxacin 400mg daily
Drug: Norfloxacin 400 MG
patients to receive nitazoxaide 500mg daily
Drug: Nitazoxanide 500 MG
patients to receive Colistin 15 ml three times daily, totalling 2,25 MIU/ day
Drug: Colistin
Patients receiving Norfloxacin 400 Mg to prevent SBP
Patients receiving Nitazoxaide 500 Mg to prevent SBP
Patients receiving Colistin 15ml three times/ day to prevent SBP
Recurrence of Spontaneous Bacterial Peritonitis (SBP)
Definition: The percentage of patients experiencing a recurrence of SBP within 6 months of treatment initiation. Measurement: Diagnosis confirmed by ascitic fluid analysis (PMN count \> 250 cells/mm³ and positive culture).
Time frame: Baseline, 3 months, and 6 months
C-Reactive Protein (CRP) Reduction
Definition: A decrease in CRP levels, indicating a reduction in systemic inflammation. Measurement: CRP levels measured in mg/L. Success Criteria: A ≥50% reduction in CRP within 3 months is considered a positive response.
Time frame: Baseline, 1 month, 3 months, and 6 months
White Blood Cell (WBC) Count Reduction
Definition: Reduction in WBC count as a marker of infection control. Measurement: WBC count measured in x10³/µL. Success Criteria: A return to normal WBC count (\<10,000/µL) by 3 months.
Time frame: Baseline, 1 month, 3 months, and 6 months
Renal Function Stability
Definition: Prevention of renal impairment during treatment. Measurement: Serum Creatinine (mg/dL) and Blood Urea Nitrogen (BUN) (mg/dL).
Time frame: Baseline, 3 months, and 6 months
Adverse Events (Safety Assessment)
Definition: Frequency and severity of treatment-related side effects (e.g., diarrhea, nephrotoxicity, hypersensitivity reactions). Measurement: Patient-reported symptoms and clinical examination findings.
Time frame: Throughout study duration (0-6 months)
Ran from Mar 2021 to primary completion in Dec 2021, 9 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Norfloxacin · Nitazoxanide · Colistin